Pradaxa Bleeding Victim Needed Transfusion, Lawsuit Says

The plaintiff in this latest lawsuit alleges she suffered significant gingival bleeding triggered by the Pradaxa medication, which caused her to be admitted to the hospital for a transfusion to treat her significant blood loss. The Alabama lawsuit is one of many to accuse the Pradaxa manufacturer of failing to warn patients of the possible hemorrhage risks associated with the drug. Originally due to start in August 2014, the first trial in the Pradaxa MDL has been expedited and is set to begin in March 2014. U.S. District Court Judge David Herndon rescheduled the start date of the trials, which are expected to run through the following year.

Pradaxa Lawsuits Expected to Increase

To date, there are approximately 200 lawsuits that are pending against Boehringer Ingelheim; however that number is believed to be unrepresentative of the actual scale of the Pradaxa problem. As stated by a recent report in the Bloomberg News, several legal experts predict that as many as 4,000 lawsuits will be filed against Boehringer in federal and state courts. Complaints have already arisen out of California, Delaware, Connecticut, Illinois and Alabama. Judge Herndon has stated that the MDL is steadily making progress but also expects to receive tens of thousands of documents with supporting evidence for both sides.

$600 Million in Pradaxa Sales Expected in 2013

Since first being introduced on to the market just over two years ago, Pradaxa has made over a billion dollars for the drug manufacturer. In 2013 alone, Pradaxa is expected to reach sales of approximately $603 million. However, it has been reported that in its first year on the market, the FDA received close to 2,400 adverse event reports. Pradaxa has been connected to hundreds of deaths in the U.S., and hundreds more are expected to file lawsuits to seek compensation for Pradaxa injuries.

Pradaxa’s success has been accredited to Boehringer’s aggressive marketing campaign when the product was released. The drug manufacturer claims that approximately 1% of the world’s population is affected by a common form of irregular heartbeat known as atrial fibrillation. According to the company’s website, the heart condition is known to cause up to three million strokes per year. Boehringer also claims that strokes caused by atrial fibrillation are severe an increased risk of death and disability.

Pradaxa is a blood thinner designed to help patients with atrial fibrillation avoid blood clots and stroke.

File Your Pradaxa Lawsuit

If you or a loved one has taken Pradaxa and has suffered from any adverse side effects directly related to the drug, you may be eligible to receive compensation. Visit our Pradaxa Internal Bleeding Class Action Lawsuit Investigation page for more information about the lawsuit against Boehringer and their drug. On our website you can submit your information to our team of specialists who can advise you on your lawsuit and how to proceed.